Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Medica Hospitalia
Damai Santosa
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Diponegoro/ Dr. Kariadi General Hospital, Jl. Dr. Sutomo, Randusar, Semarang
Biochemistry, Genetics & Molecular Biology Dentistry Health Professions Medicine & Pharmacology Nursing Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
High Leptin and Low Adiponectin Levels in The Metabolic Syndrome Patients with Malignancy Ria Ambarwati; Damai Santosa; Eko Adhi Pangarsa; Budi Setiawan; Mika Lumban Tobing; Muchlis Achsan Udji Sofro; Dharminto Dharminto; Tjokorda Gde Dalem Pemayun; Catharina Suharti
The Indonesian Biomedical Journal Vol 15, No 5 (2023)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v15i5.2567

Abstract

BACKGROUND: Metabolic syndrome (MetS), which is characterized by insulin resistance, adipocyte accumulation, and obesity, has been linked to malignancy development. Both leptin, an adipose tissue-produced cytokine-like hormone, and adiponectin, a hormone secreted by adipose tissue, play roles in the progression of MetS. However, the presence of leptin and adiponectin is also assumed to be associated with cancer proliferation. Therefore, it is necessary to investigate the profile of leptin and adiponectin levels in MetS patients with malignancy and non-malignancy.METHODS: This was a cross-sectional study involving 80 MetS subjects with and without malignancy. Leptin and adiponectin levels of subjects were analyzed by using the enzyme-linked immunosorbent assay (ELISA) method. Mann-Whitney tests were used to compare leptin and adiponectin levels between groups.RESULTS: Leptin levels were significantly higher in MetS patients with malignancy (32.99±22.47 ng/mL) than those without malignancy (6.17±7.46 ng/mL). Conversely, adiponectin levels were lower in the malignancy group (10.11±7.66 µg/mL) compared to the non-malignancy group (13.44±8.29 µg/mL), with both differences being statistically significant (p<0.001 for leptin, p=0.023 for adiponectin).CONCLUSION: Leptin levels were found to be higher while adiponectin levels were found to be lower in MetS patients with malignancy compared to those without malignancy. Therefore, it is suggested that leptin and adiponectin levels might be used as malignancy markers in MetS patients.KEYWORDS: adiponectin, leptin, metabolic syndrome, malignancy
Hiperkalemia yang Disebabkan oleh Siklosporin pada Pasien Myelodysplastic Syndrome (MDS) Puspitasari, Winda Dwi; Felista, Ratih Ayu; Santosa, Damai
Medica Hospitalia : Journal of Clinical Medicine Vol. 9 No. 1 (2022): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (277.22 KB) | DOI: 10.36408/mhjcm.v9i1.706

Abstract

Latar belakang: Siklosporin merupakan calcineurin inhibitor yang dapat digunakan sebagai imunosupresan pada myelodysplastic syndrome (MDS). Hiperkalemia adalah salah satu efek samping siklosporin. Kejadian hiperkalemia dari penggunaan siklosporin belum banyak dilaporkan. Meskipun jarang disertai dengan gejala, hiperkalemia sedang dan berat dapat menjadi fatal dan mengancam jiwa. Tujuan: Menjelaskan secara rinci mengenai hiperkalemia yang disebabkan oleh siklosporin pada pasien MDS serta penatalaksanaannya. Kasus: Seorang laki-laki (74 tahun) datang dengan keluhan melena, lemas, batuk berdahak. Pasien memiliki riwayat MDS, hipertensi, Chronic Kidney Disease (CKD), dan diabetes mellitus dan rutin minum obat siklosporin, irbesartan, dan spironolakton. Pasien mengalami hiperkalemia sejak awal masuk rumah sakit (kalium 7,8 mmol/L). Selama rawat inap, spironolakton dihentikan, irbesartan dan siklosporin dilanjutkan. Untuk terapi hiperkalemia, pasien menerima infus insulin-dekstrose dan kalsium polistirena sulfonat namun kadar kalium masih tinggi. Kalium turun ke nilai normal (4,4 mmol/L) setelah siklosporin dihentikan pada hari ke-8. Diskusi: Beberapa faktor pemicu hiperkalemia (CKD, diabetes mellitus, penggunaan bersama obat siklosporin, spironolakton, dan irbesartan) menyebabkan penanganan hiperkalemia cukup sulit. Siklosporin menyebabkan hiperkalemia melalui beberapa mekanisme yang berbeda sehingga pengaruhnya cukup kuat. Strategi penatalaksanaan hiperkalemia pada pasien ini meliputi penghentian spironolakton, pemberian insulin-dekstrose dan kalsium polistirena sulfonat, diikuti penghentian obat siklosporin. Kesimpulan: Siklosporin dapat menyebabkan hiperkalemia, sehingga penting untuk melakukan pemantauan kadar kalium secara rutin terutama bila siklosporin diberikan bersama dengan obat lain atau pada kondisi yang dapat meningkatkan kadar kalium. Kata kunci: siklosporin, hiperkalemia, myelodysplastic syndrome
Curcumin for Quality of Life of Multiple Myeloma Patients: a Randomized, Placebo-Controlled Trial: Curcumin for Quality of Life of Multiple Myeloma Patients: a Randomized, Placebo-Controlled Trial Hendrawati, Anindita Rosenda Eka; Santosa, Damai; Dharminto, Dharminto; Suharti, Catharina
Medica Hospitalia : Journal of Clinical Medicine Vol. 9 No. 2 (2022): Med Hosp
Publisher : RSUP Dr. Kariadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (292.578 KB) | DOI: 10.36408/mhjcm.v9i2.757

Abstract

Background : The main goal of multiple myeloma (MM) therapy is to control the disease, prolong the survival, and improve the life quality. Curcumin affects pro-inflammatory cytokines. There is no research yet that has been conducted to evaluate the effects of curcumin on increasing MM patient's life quality. Objective of this study is to evaluate the effect of curcumin on increasing MM patients' life quality. Methods : Of 24 MM patients were enrolled and were divided randomly into treatment groups (n=12) and controls (n=12). Patients in treatment group received melphalan 4 mg/m2, prednisone 40 mg/m2 (MP) for 7 days and curcumin 8 grams/day for 28 days. The control group received MP and placebo. Quality of life (QoL) scores were measured in early diagnosis and after 4 cycles of treatment. The difference between two groups was analyzed using Mann-Whitney U-Test or Independent T Test. Results : The role function score of the treatment group was better than control. There is a significant difference function score of patients between the treatment and control group, at baseline and 4 cycles treatment (41.66 ± 3.85 vs. 23.61 ± 3.36; 95.83 ± 1.03 vs 76.39 ± 2.51; p=0.022). There was significantly different of insomnia score between treatment and control goup at baseline and the end 4 cycles (41.67 ± 3.79 vs 58.33 ± 3.51; 9.72 ± 1.5 vs 25 ± 1.32; p=0.02). Conclusion : The addition of curcumin in myeloma patients enhances the QoL score, role function score and lowered symptom insomnia.
Co-Authors Budi Setiawan Catharina Suharti Catharina Suharti Dharminto Dharminto Dharminto Dharminto Eko Adhi Pangarsa Felista, Ratih Ayu Hendrawati, Anindita Rosenda Eka Mika Lumban Tobing Muchlis Achsan Udji Sofro Puspitasari, Winda Dwi Ria Ambarwati Tjokorda Gde Dalem Pemayun